ERBB2 and triple-negative breast carcinoma: Additionally, carboplatin-containing regimens were used for treating HER2-positive and triple negative breast cancer (TNBC) patients at a rate of approximately 25.6%, whereas HER2-targeted therapy with trastuzumab (or trastuzumab-pertuzumab in axillary lymph nodes positive patients) was given to 30% of HER2-positive cases.